Kenneth C. Cundy
2023 - Anebulo Pharmaceuticals
In 2023, Kenneth C. Cundy earned a total compensation of $495.6K as Chief Scientific Officer at Anebulo Pharmaceuticals, a 1% increase compared to previous year.
Compensation breakdown
| Bonus | $63,500 |
|---|---|
| Option Awards | $70,475 |
| Salary | $361,650 |
| Total | $495,625 |
Cundy received $361.7K in salary, accounting for 73% of the total pay in 2023.
Cundy also received $63.5K in bonus and $70.5K in option awards.
Rankings
In 2023, Kenneth C. Cundy's compensation ranked 2,033rd out of 2,978 executives tracked by ExecPay. In other words, Cundy earned more than 31.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,033 out of 2,978 | 32nd |
Division Manufacturing | 1,153 out of 1,637 | 30th |
Major group Chemicals And Allied Products | 708 out of 906 | 22nd |
Industry group Drugs | 691 out of 869 | 21st |
Industry Pharmaceutical Preparations | 496 out of 627 | 21st |
Source: SEC filing on October 30, 2023.
Cundy's colleagues
We found three more compensation records of executives who worked with Kenneth C. Cundy at Anebulo Pharmaceuticals in 2023.
News
Anebulo Pharmaceuticals CEO Simon Allen's 2023 pay falls 63% to $778K
October 30, 2023
Anebulo Pharmaceuticals CEO Simon Allen receives $2.1M in 2022
October 17, 2022
CohBar CEO Joseph Sarret receives $3.2M in 2021
April 22, 2022
CohBar CEO Steven Engle receives $2.4M in 2019
April 29, 2020
CohBar CEO Philippe Calais receives $1.6M in 2018
April 24, 2019